{"ok":true,"entry":{"slug":"dorzolamide","kind":"medication","name":"dorzolamide","aliases":["Trusopt","Cosopt"],"brands_sg":["Trusopt","Zolichek","Cosopt","Cosopt-S","Zolichek-T"],"class":"carbonic anhydrase inhibitor (ophthalmic)","tags":["other"],"use_for":"lowering eye pressure in glaucoma or ocular hypertension","use_after":"sg label: one drop three times daily when used alone","use_duration":null,"take_with":"other eye drops given at least ten minutes apart (sg label)","pros":["sg label: twice daily when added to a beta-blocker","sg label: covers open-angle and secondary glaucomas","fda: tested in children in a 3-month trial"],"cons":["fda: stinging or burning in about a third of people","fda: a bitter taste in about a quarter of people","fda: it is a sulfonamide — rare severe skin reactions"],"dose_note":"the singapore package insert for trusopt ophthalmic solution 2% (SIN08880P), as published on the moh national drug formulary, states \"When used as monotherapy, the dose is one drop of TRUSOPT Ophthalmic Solution in the affected eye(s) three times daily\" and \"When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of TRUSOPT in the affected eye(s) two times daily\" — three times a day per affected eye is the label ceiling, and the us fda label for dorzolamide 2% carries the same three-times-daily line. the same sg insert adds \"If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart\". in singapore the prescriber sets the dose.","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["sulfonamide allergy — fda warns sensitisation can recur","low corneal endothelial cell counts — fda: corneal oedema risk","hypersensitivity to any component — an sg label contraindication","acute angle-closure glaucoma needs more than pressure drops (fda)"],"clashes":[{"src":["fda_dorz_di"],"note":"fda: taking them together is not recommended — additive systemic effects","with":"oral carbonic anhydrase inhibitors (e.g. acetazolamide)"},{"src":["fda_dorz_di"],"note":"fda: acid-base and electrolyte disturbances reported with oral carbonic anhydrase inhibitors","with":"high-dose salicylate therapy"},{"src":["ndf_trusopt_dose"],"note":"sg label: different topical ophthalmic drugs given at least ten minutes apart","with":"other eye drops"},{"src":["fda_dorz_pt"],"note":"fda: the benzalkonium chloride preservative may be absorbed; lenses out first, back after 15 minutes","with":"soft contact lenses"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg dataset d_767279312753558cbf19d48344577084), Forensicclassification column; 5,511 rows cached at /tmp/hsa_all.json and filtered locally, never re-fetched — 6 dorzolamide rows","quote":"All 6 registered dorzolamide products read \"Prescription Only\" — SIN08880P TRUSOPT OPHTHALMIC SOLUTION 2% and SIN14985P ZOLICHEK 2% (single-ingredient, ATC S01EC03), plus COSOPT, COSOPT-S, ZOLICHEK-T and DORZOLAMIDE AND TIMOLOL STADA (with timolol, S01ED51).","accessed":"2026-08-27"},{"id":"ndf_trusopt_ind","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin08880p/","label":"MOH National Drug Formulary — TRUSOPT OPHTHALMIC SOLUTION 2% [SIN08880P], Indications (SG package insert)","quote":"TRUSOPT Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with: ocular hypertension; open-angle glaucoma; pseudoexfoliative glaucoma and other secondary open-angle glaucomas","accessed":"2026-08-27"},{"id":"ndf_trusopt_dose","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin08880p/","label":"MOH National Drug Formulary — TRUSOPT 2% [SIN08880P], Dosage and Administration","quote":"When used as monotherapy, the dose is one drop … in the affected eye(s) three times daily. When used as adjunctive therapy with an ophthalmic beta-blocker … two times daily … at least ten minutes apart.","accessed":"2026-08-27"},{"id":"ndf_trusopt_ci","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin08880p/","label":"MOH National Drug Formulary — TRUSOPT 2% [SIN08880P], Contraindications","quote":"TRUSOPT is contraindicated in patients who are hypersensitive to any component of this product.","accessed":"2026-08-27"},{"id":"ndf_trusopt_class","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin08880p/","label":"MOH National Drug Formulary — TRUSOPT 2% [SIN08880P], product information block","quote":"Forensic Classification: PRESCRIPTION ONLY MEDICINES · Anatomical Therapeutic Chemical (ATC) code S01EC03 · Prescription-only Medicines with Exemptions for Supply without Prescription: NA","accessed":"2026-08-27"},{"id":"fda_dorz_ind","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2% (Sagent), section 1, via openFDA drug/label.json (effective 2026-01-09)","quote":"Dorzolamide Hydrochloride Ophthalmic Solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.","accessed":"2026-08-27"},{"id":"fda_dorz_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2%, section 2, via openFDA","quote":"The dose is one drop of Dorzolamide Hydrochloride Ophthalmic Solution in the affected eye(s) three times daily … If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.","accessed":"2026-08-27"},{"id":"fda_dorz_warn","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2%, section 5 Warnings and Precautions, via openFDA","quote":"contains dorzolamide, a sulfonamide … Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome … Sensitization may recur … increased potential for developing corneal edema in patients with low endothelial cell counts.","accessed":"2026-08-27"},{"id":"fda_dorz_ae","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2%, section 6 Adverse Reactions, via openFDA","quote":"ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste … Superficial punctate keratitis occurred in 10 to 15% of patients","accessed":"2026-08-27"},{"id":"fda_dorz_di","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2%, section 7 Drug Interactions, via openFDA","quote":"The concomitant administration of Dorzolamide Hydrochloride Ophthalmic Solution and oral carbonic anhydrase inhibitors is not recommended … toxicity associated with high-dose salicylate therapy … the potential for such drug interactions should be considered","accessed":"2026-08-27"},{"id":"fda_dorz_ped","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2%, section 8.4 Pediatric Use, via openFDA","quote":"Safety and effectiveness of Dorzolamide Hydrochloride Ophthalmic Solution have been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-treatment-controlled trial.","accessed":"2026-08-27"},{"id":"fda_dorz_pt","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dorzolamide+hydrochloride%22&limit=5","label":"US FDA label for Dorzolamide Hydrochloride Ophthalmic Solution 2%, section 17 Patient Counseling Information, via openFDA","quote":"contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following … administration.","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:18.585742+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}